Retatrutide is an investigational medication that has not been approved by regulatory authorities for any use. The information in this article is provided strictly for educational purposes and should not be interpreted as medical advice. Hair changes during weight loss can have many causes. Anyone experiencing hair shedding should consult a qualified healthcare professional for proper evaluation and guidance. Self-treatment or sourcing unapproved medications carries significant risks.
Direct Answer
Based on currently available clinical trial data, retatrutide does not appear to directly cause hair loss. Hair loss has not been identified as a common or prominent side effect in published studies of retatrutide.
However, some individuals using medications that produce substantial and rapid weight loss — including certain GLP-1 receptor agonists — have reported increased hair shedding. In most cases, this is believed to be related to the physiological effects of rapid weight reduction rather than a direct toxic effect of the medication on hair follicles.
What Do Retatrutide Clinical Trials Show?
In the Phase 2 trial published in the New England Journal of Medicine (2023), the most frequently reported side effects were gastrointestinal in nature, such as nausea, diarrhea, and constipation. Hair loss or alopecia was not highlighted as a notable adverse event in the safety analysis.
Similarly, topline results from the Phase 3 TRIUMPH-1 trial (released in May 2026) listed the most common side effects as gastrointestinal issues, along with some reports of increased heart rate and skin sensation changes in certain dose groups. Hair loss was not reported as a frequent or dose-related adverse event in the publicly available summaries.
Because retatrutide remains investigational, long-term safety data are still being collected. It is possible that rarer side effects may emerge as more participants are studied over longer periods. At present, however, there is no strong clinical trial evidence linking retatrutide directly to hair follicle damage or permanent hair loss.
Why Hair Shedding Can Occur During Significant Weight Loss
A common form of temporary hair shedding is called telogen effluvium. This occurs when a physical stressor pushes a larger-than-normal percentage of hair follicles into the resting (telogen) phase of the hair growth cycle. After several weeks to months, these hairs shed, leading to noticeable thinning or increased hair fall.
Significant and rapid weight loss is a well-recognized trigger for telogen effluvium. This can happen with:
- Very low-calorie diets
- Bariatric surgery
- Certain medications that cause substantial weight reduction
The mechanism is thought to involve a combination of factors, including:
- Calorie and nutrient deficit
- Rapid reduction in body fat stores
- Hormonal shifts
- Physical stress on the body
This type of shedding is usually temporary. In most cases, hair regrowth occurs once weight stabilizes and nutritional intake improves, typically within 6–12 months.
Evidence from Related Weight Loss Medications
Other medications in the same broader class have reported alopecia or hair loss in their prescribing information:
- In clinical trials for semaglutide (Wegovy), alopecia was reported in approximately 3.5% of participants compared to 1% on placebo.
- Tirzepatide (Mounjaro/Zepbound) prescribing information also lists alopecia as a possible adverse reaction.
Research and clinical observations suggest that the hair shedding seen with these medications is largely attributable to the rapid weight loss they produce rather than a direct pharmacological effect on hair follicles. Some studies have noted higher reporting of telogen effluvium and, in certain cases, androgenic alopecia among users of GLP-1 receptor agonists. However, many dermatologists and researchers emphasize that this shedding is often reversible and linked more to the metabolic stress of weight loss than to the drug itself.
Because retatrutide has demonstrated even greater average weight loss in trials (up to 28%+ in Phase 3 data), it is reasonable to consider that some users might experience similar temporary shedding if weight loss occurs quickly. However, this has not been prominently observed or reported in retatrutide-specific trial publications to date.
Factors That May Influence Hair Health During Weight Loss
Several factors can increase the likelihood or severity of hair shedding during periods of significant weight reduction:
- Rate of weight loss — Losing weight very rapidly (more than 1–1.5 kg per week consistently) appears to raise the risk.
- Nutritional intake — Inadequate protein, iron, zinc, biotin, vitamin D, or overall calories can contribute to hair shedding.
- Pre-existing hair conditions — Individuals with a genetic predisposition to androgenic alopecia or other hair disorders may notice changes more readily.
- Overall health status — Stress, hormonal imbalances, thyroid issues, or other medical conditions can compound the effect.
Maintaining a balanced diet with sufficient protein (generally 1.2–1.6 g per kg of body weight or as advised by a professional) and key micronutrients may help support hair health during weight management.
What to Do If You Notice Increased Hair Shedding
If you are experiencing noticeable hair loss while using any weight management medication or following a significant weight loss program:
- Consult a healthcare professional — A doctor or dermatologist can help determine whether the shedding is telogen effluvium or related to another cause.
- Review nutrition — Ensure adequate protein intake and consider checking levels of iron, ferritin, vitamin D, zinc, and B vitamins.
- Be patient — Telogen effluvium is typically self-limiting. Hair usually begins to regrow once the triggering factor stabilizes.
- Avoid harsh hair treatments — Minimize heat styling, chemical treatments, and tight hairstyles during periods of increased shedding.
- Discuss with your prescriber — They may adjust the rate of dose escalation or provide guidance tailored to your situation.
It is important not to stop any prescribed medication without medical advice, as this can have other health consequences.
Conclusion
Current clinical trial data for retatrutide do not indicate that the medication directly causes hair loss or permanent damage to hair follicles. Any hair shedding that occurs in association with retatrutide or similar medications is more likely related to the significant and sometimes rapid weight loss these treatments can produce.
Telogen effluvium triggered by rapid weight reduction is generally temporary and reversible for most people. Maintaining good nutrition, ensuring gradual and sustainable weight loss where possible, and seeking professional medical advice if shedding becomes concerning are the most appropriate steps.
As more long-term data from ongoing Phase 3 trials become available, our understanding of retatrutide’s full safety profile will continue to evolve. Until the medication receives regulatory approval, it should only be used within properly supervised clinical trial settings.
This article is intended to provide balanced, research-based information to help readers understand the current evidence. It is not a substitute for personalized medical advice.